ArticleThe World Allergy Organization journal2026
Analyzing the clinical profile and potential biomarkers to differentiate idiopathic angioedema from hereditary or mast cell-mediated angioedema.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Idiopathic angioedema (AE-UN) is a heterogeneous, exclusion-based clinical category rather than a single disease entity. The clinical characteristics and potential exploratory markers in patients currently classified as AE-UN remain poorly understood. This study aimed to evaluate clinical features and laboratory mediators in a selected cohort of patients fulfilling the current diagnostic definition of AE-UN. Methods: We compared 16 patients classified as AE-UN according to a stepwise diagnostic approach with 20 patients with hereditary angioedema (HAE), 20 patients with mast cell-mediated angioedema (AE-MC), and 24 healthy controls. AE-MC classification required recurrent angioedema with or without wheals, normal C4 and C1-inhibitor levels, and a convincing clinical response to mast cell-directed therapy, including H1-antihistamines up to four-fold standard dose when clinically indicated, corticosteroids, or standard-dose omalizumab (4-6 months). Patients without such a response and without confirmed HAE, drug-induced angioedema, or other recognized causes were classified as AE-UN. Baseline features, treatments, and laboratory factors were analyzed, including serum markers of inflammation, endothelial dysfunction, and serine proteases, as determined by ELISA. Results: AE-UN showed shorter disease duration compared to AE-MC and HAE (2.26 vs. 3.02 vs. 15.78, p < 0.0001), but experienced a relatively higher frequency of life-threatening attacks than AE-MC (25% vs. 10%). Meanwhile, facial edema was most common in AE-UN (68.75%). We did not find a significant difference regarding age and sex among all angioedema (AE) subtypes. IgG4 levels were increased in AE-UN rather than other AE groups, and demonstrated a statistical difference with HAE (p = 0.049). Besides, Ang-1, Ang-2, and Tie-2 were significantly elevated in all AE compared to controls. By contrast, the Ang-2/Ang-1 ratio was decreased in AE patients. Notably, in AE-UN compared to AE-MC and HAE, Fibroblast Activation Protein (FAP) concentration was significantly reduced, whereas for tPA and PLA2G7, the difference was not significant compared to controls and among AE subtypes. Conclusions: Lower FAP levels may represent an exploratory biomarker candidate in this selected AE-UN cohort, rather than a diagnostic marker for a homogeneous disease. Ang-1, Ang-2, and Tie-2 were increased across angioedema groups. Because of the small sample size, the exclusion-based nature of AE-UN, and the possibility of diagnostic reclassification, these findings should be interpreted as hypothesis-generating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.